Oncology

How Can Value-Based Care Embrace the Possibilities of Biosimilars?

February 3rd 2020

By Sara Karlovitch

In case you missed it: Jeffery Scott, MD, chief medical officer of Integra Connect, discussed what role biosimilars will play in a value-based system on a recent podcast episode of Not So Different.

Trust, Planning Key to a Successful Biosimilar Launch, Panelists Say

January 24th 2020

By Tony Hagen

Panelists at the 2020 Specialty Therapies and Biosimilars Congress discussed the strategies needed to get biosimilars to market and overcome obstacles by originator product manufacturers.

The Biosimilar Solution to Expensive Cancer Care

January 20th 2020

By Maggie L. Shaw

In May 2019, the FDA released its final guidance on biosimilars. With more and more oncology biosimilars entering the market, healthcare providers should be able to help their patients reduce their out-of-pockets costs while providing the highest-quality care available, which will lead to savings over time, according to a recent column in Evidence-Based Oncology™, a sister publication to The American Journal of Managed Care®.

The Top 5 Biosimilars Articles for the Week of January 6

January 11th 2020

The Center for Biosimilars® recaps the top stories for the week of January 6.

FDA Touts Biosimilar Approvals in Annual CDER Report

January 8th 2020

By The Center for Biosimilars Staff

In 2019 the FDA approved 48 novel drugs and 10 biosimilars, according to the Center for Drug Evaluation and Research (CDER).

Spectrum Says Its Novel G-CSF Drug Will Be Reviewed by FDA

January 4th 2020

In late December, Spectrum Pharmaceuticals announced that the FDA has accepted for review a Biologics License Application for eflapegrastim, a novel drug that could, if approved, compete with existing granulocyte colony-stimulating factor (G-CSF) therapies and their biosimilars.

Bevacizumab Study Shows Influence of Physician Relationships on Prescribing

January 4th 2020

By The Center for Biosimilars Staff

The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies.

Using Biosimilar Filgrastim May Lead to Shorter Hospitalization, Lower Cost in PBSC Mobilization

January 3rd 2020

By Kelly Davio

Using the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.

Sonia T. Oskouei, PharmD: Biosimilars in 2020

January 1st 2020

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.

Lee Schwartzberg, MD, FACP: Biosimilars and Patient Attitudes

December 27th 2019

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.